The progression of non-alcoholic fatty liver disease (NAFLD) is affected by epigenetics. We undertook comethylation and differentially methylated region (DMR) analyses to identify the genomic region that is under epigenetic regulation during NAFLD progression.
INTRODUCTION
N ON-ALCOHOLIC FATTY LIVER disease (NAFLD) is a disease concept characterized by the accumulation of fat (mainly triglycerides) in hepatocytes, and includes a wide spectrum of liver diseases, ranging from nonalcoholic fatty liver, which is a benign and non-progressive condition, to non-alcoholic steatohepatitis, which can progress to liver cirrhosis and hepatocellular carcinoma. 1, 2 Non-alcoholic fatty liver disease has become a common disorder associated with metabolic syndrome in developed countries, and the prevalence of the disease continues to increase in Japan. 3, 4 In light of the rapid increase in hepatocellular carcinoma resulting from NAFLD, investigating the pathogenesis of NAFLD represents an urgent task.
Recent progress in genetic and epigenetic analyses has provided novel insights into the pathogenesis of NAFLD development and progression. 5, 6 In particular, we have reported a genetic background that predisposes to the development of NAFLD in the Japanese population. [7] [8] [9] Specifically, the patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 single nucleotide polymorphism (SNP) was identified to be the most predictive variant for NAFLD; its frequency is much higher in Japanese compared with White and Black populations. Using targeted next-generation sequencing, we constructed a high-resolution linkage disequilibrium block containing rs738409 and reported that variants in SAMM50 sorting and assembly machinery component (SAMM50) and parvin β (PARVB) are also associated with the development and progression of NAFLD. 9 Targeted bisulfite sequencing indicated hypermethylation of CpG99 in the regulatory region of PNPLA3 and subsequent suppression of PNPLA3 mRNA levels were observed in the livers of patients with NAFLD with advanced fibrosis. 10 Conversely, CpG26 in the regulatory region of PARVB was markedly hypomethylated in the livers of patients with NAFLD with advanced fibrosis. We further undertook RNA sequencing using liver biopsy specimens and created a weighted gene co-expression network analysis, which allowed us to identify the core gene networks and hub genes involved in NAFLD progression. 11 Investigation of whole transcriptomes in the livers of patients with NAFLD provided new insights into the pathogenesis of NAFLD progression. These data indicated that progression of NAFLD arises from the interaction of several genes and environmental factors that affect hepatic DNA methylation and subsequent gene expression.
DNA methylation analysis represents one of the most important methods to evaluate the epigenetic status in the liver in NAFLD. However, no studies have yet reported genome-wide DNA methylation analyses in the liver of Japanese patients with NAFLD, although a few genomewide DNA methylation analyses of NAFLD livers were reported in other populations. 12, 13 Differentially methylated regions (DMRs), which comprise multiple consecutive methylated CpG sites, have important implications for disease development and progression compared with single CpG sites. Despite the interest in DMRs associated with NAFLD, none have been reported to date.
In this study, we present the systematic analysis of DNA methylation in the liver of patients with NAFLD during NAFLD progression. Using two approaches, comethylation and DMR analyses, we determined the genes that are under epigenetic regulation and are associated with NAFLD progression.
METHODS

Subjects
T HIS STUDY WAS carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from each participant and the protocol was approved by the ethics committees at Osaka University (Osaka, Japan), Kyoto University (Kyoto, Japan), and Yokohama City University (Yokohama, Japan). We enrolled 60 Japanese patients with NAFLD who had undergone liver biopsy at Yokohama City University Hospital. In accordance with previously described exclusion criteria, [7] [8] [9] [10] [11] we excluded patients with viral hepatitis owing to hepatitis B and C, as well as those with Epstein-Barr virus, autoimmune hepatitis, primary biliary cholangitis, sclerosing cholangitis, hemochromatosis, α 1 -antitrypsin deficiency, Wilson disease, drug-induced hepatitis, and alcoholic liver disease (present or past consumption exceeding 20 g alcohol per day). None of the patients presented with hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, or serum bilirubin more than two-fold higher than the normal upper limit. Nonalcoholic fatty liver disease was diagnosed according to standard criteria. [14] [15] [16] Steatosis was graded according to the percentage of hepatocytes with macrovesicular fat droplets 17 and NAFLD activity was determined based on the composite NAFLD activity score. 18 Fibrosis was staged at 0-4 according to Brunt, 17 and patients were classified as having mild (fibrosis stages 0-2, n = 35) or advanced (fibrosis stages 3-4, n = 25) NAFLD.
DNA methylation analysis
Genomic DNA was extracted from frozen liver biopsy specimens. Samples of 500 ng genomic DNA were reacted with bisulfite using the Zymo EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's protocol. Genome-wide DNA methylation levels were determined using the Illumina Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA). GenomeStudio v2011.1 and Methylation Module v1.9.0 (Illumina) were used to generate raw β-values for each CpG site, ranging from 0 (completely unmethylated) to 1 (completely methylated). Raw DNA methylation data were preprocessed by normalizing to appropriate internal control probes. Probes with intensities indistinguishable from the background (detection P-value >0.05) in more than one sample, probes with a bead count <3 in at least 5% of samples, SNP probes, and cross-reactive probes were excluded. The effects of two types of CpG probes on CpG methylation measurements were corrected using beta-mixture quantile normalization, 19 and batch effects were corrected using a ComBat normalization method 20 in the R/Bioconductor package ChAMP. 21 After these procedures, 431 736 CpG sites were extracted, differentially methylated CpG sites were identified using limma, 22 and the DMRs between mild and advanced NAFLD were identified using the Probe Lasso method. 23 Hepatic DNA methylation data for NAFLD from an American cohort (NCBI Gene Expression Omnibus accession number GSE31803), 13 were used for replication analysis. GSE48325 data 12 were used for the effects of weight loss by bariatric surgery on hepatic DNA methylation levels. Differentially methylated CpG sites between mild (fibrosis stages 0-1; n = 33) and advanced (fibrosis stages 3-4; n = 23) in GSE31803, or before (n = 22) and after (n = 22) bariatric surgery of GSE48325, were calculated using limma, and DMRs were determined using the Probe Lasso method over 431 736 CpG sites.
Co-methylation analysis
To assess the intercorrelation among the differentially methylated CpG sites between mild and advanced NAFLD, a co-methylation analysis was carried out using the weighted gene co-expressed network analysis (WGCNA) R package to construct a consensus module. 24, 25 In this analysis, a network was represented by the adjacency matrix A = [α ij ], where α i,j is |PCC i,j | β , PCC i,j is the Pearson correlation coefficient between methylation levels of CpG probes i and j across samples, and β is a soft threshold. β was set at 18, the smallest value at which one co-methylation network exhibited scale-free properties with a model-fitting index R 2 > 0.70. CpG probes were clustered based on topological overlap, 26 a measure of co-methylation interconnectedness between probes, and were assigned to a module (a group of densely co-methylated probes) using Dynamic Tree Cut. 25 Gene ontology (GO) 27 enrichment analysis was executed using the Bioconductor packages GO.db, AnnotationDbi, and org.Hs.eg.db (http://www.bioconductor.org).
Relationship between DMRs and gene expression
To compare the DMRs with the expression of their associated genes, we utilized the RNA sequencing data of our recently published Japanese NAFLD cohort (JGAS00000000059; http://trace.ddbj.nig.ac.jp/jga/index. html). 11 The fragments per kilobase of transcript per million were determined and differences between 39 mild (fibrosis stage 0-2) and 21 advanced (fibrosis stage 3-4) NAFLD livers were calculated using TopHat2 version 2.0.13 and Cufflinks version 2.2.1, 28 as previously reported. 11 Genes were considered to be differentially expressed at false discovery rate (FDR) q-values <0.05.
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Among the 60 subjects with available RNA sequencing data, 56 (35 mild and 21 advanced NAFLD) also participated in the DNA methylation analysis. GSE31803 (Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays) data were also used for expression analysis. 13, 30 The expression data of GSE31803 were derived from liver samples of American patients with NAFLD (40 mild (fibrosis stage 0-1) and 32 advanced (fibrosis stage 3-4) NAFLD). Differential gene expression was determined using limma. 22 Genes were considered differentially expressed at FDR q-values <0.05.
Other statistical analysis
Clinical data were compared using t-tests between patients with mild or advanced NAFLD. Fisher's exact test was used to analyze the male to female ratio, as well as the prevalence of type 2 diabetes. Data were analyzed in R (http:// www.r-project.org/).
Data access
HumanMethylation450 BeadChip data are available from the Japanese Genotype-Phenotype Archive under the accession number JGAS00000000059 (http://trace.ddbj. nig.ac.jp/jga/index.html).
RESULTS
Differentially methylated CpG sites in livers with mild or advanced NAFLD W E EXTRACTED GENOMIC DNA and measured the methylation levels from frozen liver biopsy specimens obtained from 35 Japanese patients with mild NAFLD and 25 patients with advanced NAFLD. The clinical and pathological data are shown in Table 1 . After normalization and batch correction, 59 858 CpG sites among the 431 736 that existed in the autosome showed differential methylation between mild and advanced NAFLD (FDR q < 0.05). We undertook a replication study using the American NAFLD cohort dataset and identified further definite differentially methylated CpGs between mild and advanced NAFLD. A total of 25 936 CpG sites (8596 hypermethylated and 17 340 hypomethylated) were identified. Many CpG sites were hypomethylated in Japanese advanced NAFLD samples, as observed in a previous report. 13 The features of these differentially methylated CpGs are shown in Figure S1 . Notably, many differentially methylated CpG sites in the livers between mild and advanced NAFLD were observed outside of CpG islands; instead, they were located in the gene bodies or intergenic regions. These differentially methylated CpG sites included some, but not all, of the previously reported CpG sites: 12, 13 cg01385327 in the fibroblast growth factor receptor 2 (FGFR2) gene, cg16367511 in the methylenetetrahydrofolate dehydrogenase (nicotinamide adenine dinucleotide 
Co-methylation analysis of differentially methylated CpG sites
Previous reports indicated that consensus modules represent common and robust co-methylation relationships, which reflect the underlying biological characteristics rather than technical artifacts, such as batch effects, as they are present in independent datasets. 31, 32 In addition, weighted network methods are particularly useful to identify consensus modules. Therefore, we used WGCNA to construct a consensus module using 25 936 significantly differentially methylated CpG sites in livers from Japanese and American patients with NAFLD. As indicated in Figure 1 , differentially methylated CpG sites in the NAFLD liver were clustered into three modules: module 1 (12 913 CpG sites), module 2 (7794 CpG sites), and module 3 (1224 CpG sites). The 4005 CpG sites in module 0 were not significantly co-methylated. The methylation levels of the CpG sites in module 2 correlated with increased 
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Type IV collagen 7 s, ng/dL 4.3 ± 0. Values represent mean ± standard deviation. Clinical data between mild and advanced NAFLD were compared using a t-test. †Ratios analyzed using Fisher's exact test. ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; ChE, cholinesterase; GGT, γ-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; NAS, NAFLD activity score; PT-INR, international normalized ratio of prothrombin time.
fibrosis stage, whereas those in modules 1 and 3 were correlated with decreased fibrosis stage in the livers of Japanese patients with NAFLD ( Fig. 1) . Differentially methylated CpG sites were annotated to 7862 genes and the annotated genes were subjected to GO enrichment analysis. The genes with CpG sites in module 1 were enriched in the biological process of "immune response", or "lymphocyte and leukocyte activations" ( Table 2 ). The methylation levels of the CpG sites in module 1 were decreased in advanced NAFLD; therefore, these results suggested that the expression of genes related to immune response and inflammation increase and cause hepatocyte inflammation in the livers of patients with advanced NAFLD. The genes with differentially methylated CpG sites in module 2 were enriched in cellular components of "mitochondria" or "lipid particle", the biological process of "metabolism" (especially lipid metabolism), and the molecular function of "oxidoreductase activity". The methylation levels of the CpG sites in module 2 were increased in advanced NAFLD; therefore, the expression of genes located in the mitochondria and related to lipid metabolism and oxidoreductase activity would be expected to be reduced in the livers of patients with advanced NAFLD, resulting in impaired lipid and oxidation metabolism 33, 34 and reduced mitochondrial function. [35] [36] [37] In turn, the genes with differentially methylated CpG sites in module 3 were enriched in the cellular components of "cell periphery" or "plasma membrane". Their methylation levels were decreased in advanced NAFLD.
Differentially methylated regions between mild and advanced NAFLD livers
Differentially methylated regions have important implications for diseases compared with those associated with single CpG sites. 38 Therefore, we extracted DMRs between mild and advanced NAFLD livers from among 431 736 CpG sites using the Probe Lasso method. 23 We obtained 1493 DMRs between Japanese mild and advanced NAFLD. A total of 610 DMRs were replicated in the American cohort containing 3683 CpGs (Table S1 ). Among all of the DMRs, 200 were hypermethylated, 380 were hypomethylated, and 30 were in transition from a hypermethylated to a hypomethylated status, or vice versa. The most significant DMR was observed in the genomic region of the FGFR2 gene (Fig. 2 ). In addition, as shown in Table 3 , the DMRs also included microRNA (miRNA) genes. MicroRNAs are known to play important roles in fibrosis and tumorigenesis in the liver. Accordingly, ten miRNA genes located in eight DMRs are involved in the Kyoto Encyclopedia of Genes and Genomes pathway "MicroRNAs in cancer" 39 ( Fig. S2) . Notably, the DMR containing the oncogene MIR21 was hypomethylated in the liver of advanced NAFLD, which is consistent with the increased MIR21 expression observed in hepatocellular carcinoma. 40, 41 The DMRs and the P-values between mild and advanced NAFLD were determined using the Probe Lasso method. 23 Genes in bold were included in the Kyoto Encyclopedia of Genes and Genomes category hsa05206 "MicroRNAs in cancer". Chr; chromosome. ). The WNT1-inducible signaling pathway protein 1 (WISP1) gene was associated with a hypermethylated DMR; however, its expression was upregulated in advanced NAFLD. The gene encoding O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, contained two DMRs. The DMR located in the gene body closer to the transcription start site was hypomethylated, whereas the other, also in the gene body, was hypermethylated. The expression of MGMT was downregulated in advanced NAFLD. The DMR in the gene encoding superoxide dismutase 3, extracellular (SOD3), which reduces superoxide radicals, was hypomethylated in the sequence region from À1500 to À200 bp upstream of the transcription start site, and hypermethylated in the region from À200 bp upstream of the transcription start site, and in the 5 0 -untranslated region. The expression of SOD3 was upregulated in advanced NAFLD.
Reversal of DMRs through weight reduction by bariatric surgery
To determine whether DMRs in the NAFLD liver are reversible and could respond to treatment, we analyzed the above 610 DMRs using the hepatic methylation dataset of samples from patients before and after weight reduction by bariatric surgery. 12 The hepatic methylation data of 22 subjects (17 NAFLD and five normal obese) were available. The body mass indexes decreased from 49.9 to 35.5 kg/m 2 and 13 subjects with non-alcoholic steatohepatitis or simple steatosis recovered to simple steatosis or a normal liver, respectively. Among the 610 DMRs, only seven, which were hypermethylated in advanced NAFLD, responded with a decrease in methylation levels after bariatric surgery (Fig. S4) 
DISCUSSION
U SING CO-METHYLATION ANALYSIS, individual differentially methylated CpG sites were clustered into three modules. Differentially methylated CpGs clustered in module 2 were hypermethylated in the livers of patients with advanced NAFLD. The proteins encoded by the genes containing these CpGs were determined to be located in mitochondria or lipid particles, and are involved in lipid metabolism and/or in the oxidoreductase reaction. These results were consistent with those of our previous RNAsequencing analysis, in which downregulated genes in the livers of patients with advanced NAFLD were functionally enriched in the cellular component of mitochondrial location and in the biological process of oxidoreductase activity. 11 Considering the co-methylation and RNAsequencing analyses, the overall expression of oxidoreductase activity-related genes was reduced, which would increase the sensitivity of the advanced NAFLD liver to oxidative stress. These findings support previous reports that lipotoxic and oxidative stress, 33 as well as reduced mitochondrial respiratory chain function, 34, 35 may constitute the factors underlying the progression of the NAFLD liver from a non-alcoholic fatty liver to nonalcoholic steatohepatitis. 36 In turn, the differentially methylated CpG sites clustered in module 1, which were hypomethylated, included genes functionally enriched in the immune response, and in lymphocyte and leukocyte activation. Decreased hepatic DNA methylation would be expected to increase the expression of inflammationrelated genes, leading to hepatocyte inflammation. Body, gene body; Chr, chromosome; open sea, isolated CpG sites in the genome; shelf, CpG sites existing in a region 2-4 kb from CpG islands; shore, CpG sites existing up to 2 kb from CpG islands; TSS1500, the sequence region from À200 to À1500 bp upstream of the transcription start site (TSS); TSS200, the region from À200 bp upstream of the TSS; UTR, untranslated region.
The identification and characterization of DMRs between mild and advanced NAFLD was of prime interest with respect to epigenetic mechanisms, and highlighted the key genes. However, DMRs in NAFLD have not been reported; therefore, this is the first report to identify DMRs with suggestive driver genes related to NAFLD progression. The most notable DMRs identified in this study were associated with tumorigenesis-related genes. In particular, MIR21 is an oncogene whose expression is increased in hepatocellular carcinoma. 40, 41 The DMR that included the MIR21 gene was hypomethylated in the livers of patients with advanced NAFLD. Consistent with this finding, circulating miRNA-21 levels were reported to be increased in patients with non-alcoholic steatohepatitis compared with those with non-alcoholic fatty liver and control subjects. 42 Therefore, the DMR containing the MIR21 gene likely regulates the levels of circulating miRNA-21 and might be related to the tumorigenesis status in livers of patients with advanced NAFLD. In turn, PDGFA and FGFR2 are related to cancer development through the Ras, mitogen-activated protein kinase, Rap1, phosphatidylinositol 3-kinase/Akt, and epidermal growth factor receptor (EGFR) tyrosine kinase signaling pathways. 39 The ZBTB38 protein product is reported to control replication and genome stability, and its increased expression causes DNA damage. 43 WNT1-inducible signaling pathway protein 1 activates the antiapoptotic Akt/PKB signaling pathway and protects cells from suppressor protein p53-dependent cell death. 44 In the present study, we showed that expression of these tumorigenesis-related genes was increased in the livers of patients with advanced NAFLD, under the possible regulation of DNA methylation. The MGMT protein is involved in the repair of DNA damage and acts as a tumor suppressor. Increased methylation of the promoter region of the MGMT gene has been reported in hepatocellular carcinoma. 45 In the present study, two DMRs were identified in the body of the MGMT gene, one of which was hypomethylated and the other was hypermethylated. The expression of MGMT was downregulated in the livers of patients with advanced NAFLD. Although the DMRs were not in the promoter region, the presence of two DMRs in the MGMT gene would likely affect the expression level and thereby play important roles in hepatic tumorigenesis of patients with advanced NAFLD. In contrast, the mRNA expression of the genes encoding filamin binding LIM protein 1 (FBLIM1) and CYR61, which decrease cell proliferation, 46, 47 was increased in the livers of patients with advanced NAFLD in association with hypomethylated DMRs. These results suggested that, in the livers of patients with advanced NAFLD, there is an antagonistic state between tumorigenesis and tumor suppression.
The identified DMRs included those that contained antioxidant genes NQO1 and SOD3, the expression of which increased in the livers of patients with advanced NAFLD.
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NQO1 and SOD3 upregulation might play an important role in protecting the liver from oxidative stress in advanced NAFLD. The genes involved in various metabolic pathways contained hypermethylated DMRs and showed downregulated expression. Thus, the reduction in metabolism in the livers of patients with advanced NAFLD appeared to occur at the level of DNA methylation, which was consistent with the results of the co-methylation analysis. Those DMRs were not restored after weight reduction, suggesting that genes possessing those DMRs were under irreversible epigenetic regulation and act as driver genes during NAFLD progression.
The methylation levels of seven DMRs changed after weight reduction. The MIR192/194-2 genes are involved in the pathway of cancer. Hepatocyte nuclear factor 4α regulates expression of MIR192 and MIR194-2.
49 NUPR1 is induced by stress or mitochondrial dysfunction, and plays an important role in the growth and migration of human tumor cells. 50 The methylation levels of these genes were increased in advanced NAFLD and decreased after weight reduction. These results suggest that increased methylation levels of MIR192/194-2, HNF4A, and NUPR1 would reduce the risk of tumorigenesis in the advanced NAFLD liver.
C2, C3, and CFB are involved in the complement cascade. Chitinase domain-containing 1 binds saccharide and lipopolysaccharide, and has possible roles in pathogen sensing and endotoxin neutralization. 51 The methylation levels of C2, C3, CFB, CHID1, and ABCG5 were increased in advanced NAFLD, and decreased after weight reduction. Thus, C2, C3, CFB, and CHID1 would be candidate targets for NAFLD treatment, to protect the liver from pathogens and endotoxins. ATP binding cassette subfamily G member 5 selectively excretes sterol into bile. The decreased methylation of ABCG5 after weight reduction would result in increased excretion of sterol into bile to protect against lipotoxicity, 33 and would be a good candidate target for treatment.
In summary, we showed, using co-methylation and DMR analyses, that the reduced mitochondrial function, oxidoreductase activity, and metabolism in the liver of patients with advanced NAFLD occurred at the level of DNA methylation. The liver of advanced NAFLD appeared to be in a transitional tumorigenesis status, which was also manifested at the level of DNA methylation. Therefore, our data might provide useful information to help understand ongoing pathogenic phenomena in the liver of advanced NAFLD. We also identified the possible driver genes involved in NAFLD progression and candidate target genes for treatment.
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A DDITIONAL SUPPORTING INFORMATION may be found online in the supporting information tab for this article. Table S1 . Significant differentially methylated regions between mild and advanced non-alcoholic fatty liver disease Figure S1 . Features of differentially methylated CpG sites. Figure S2 . Kyoto Encyclopedia of Genes and Genomes category hsa05206 "microRNAs in cancer". Figure S3 . Differentially methylated regions and the expression of 24 associated genes. Figure S4 . Differentially methylated regions between mild and advanced non-alcoholic fatty liver disease and before and after weight reduction.
